Compound Vitamin B Veterinary Grade API is a multi-component B-vitamin active pharmaceutical ingredient or prepared substance intended for the manufacture of veterinary medicinal products in tablets, injections, capsules, powders, granules, premixes, and oral or parenteral solutions. The material is not a single chemical entity; it is a defined blend or co-processed system of water-soluble and sparingly water-soluble B vitamins, typically containing thiamine hydrochloride, riboflavin or riboflavin 5′-phosphate sodium, nicotinamide or nicotinic acid, calcium D-pantothenate, pyridoxine hydrochloride, biotin, folic acid, and cyanocobalamin. No universal pharmacopoeial model designation exists; manufacturers assign internal product codes for traceability, such as CVB-VET-API with a suffix indicating intended dosage-form grade, for example CVB-VET-API-PM for premix grade and CVB-VET-API-IMG for injectable-grade milled material. The exact composition ratio is not fixed; it is adjusted to species-specific requirements, dosage form, and the regulatory file of the finished veterinary medicinal product.

The API can be supplied as a homogeneous powder, stabilised granule, or pre-solubilised liquid concentrate, with the physical form selected according to the dosage-form process. Finished-product manufacturers should request a certificate of analysis containing identity, assay, loss on drying, residue on ignition, heavy metals, residual solvents, microbial enumeration, and particle size distribution. For injectable grade, bacterial endotoxins and bioburden data are additional release parameters.

The compendial status of the mixture differs from the status of the individual components. Each active substance may comply with its own pharmacopoeial monograph, while the combined API is controlled by the finished-product marketing authorisation and the manufacturing requirements of the intended veterinary medicinal product.

Why does premix homogeneity depend on particle size distribution and electrostatic charge accumulation?

The distribution of low-dose B vitamins in a veterinary premix is controlled by the same particle mechanics that govern dry powder mixing. The API is characterised by laser diffraction according to ISO 13320:2020 and sieve analysis according to Ph. Eur. 2.9.38. For premix grades, particle size specifications are usually set on the basis of carrier particle size; a common process-development target is D90 ≤ 450 µm and D10 ≥ 20 µm to reduce segregation during transfer and handling. Finished-product manufacturers may require a narrower distribution when the active mixture will be diluted in a 1:100 or 1:1000 premix. Low-dose components such as cyanocobalamin and biotin require a two-step dilution, because direct addition of a concentrated B-vitamin blend to a mineral or cereal carrier can produce unacceptable content variation.

Flow behaviour of the API is evaluated through bulk and tapped density according to Ph. Eur. 2.9.34. A Hausner ratio below 1.25 is generally acceptable for transfer and filling; values above 1.35 indicate a cohesive powder that may require glidant addition or granulation. Riboflavin and folic acid can accumulate electrostatic charge in low-humidity environments, causing adhesion to stainless steel surfaces and uneven distribution in tumble blenders or ribbon mixers. Processing at 40–60% RH is often used to suppress static while avoiding moisture uptake by hygroscopic components. Blend uniformity is assessed by sampling at 10–20 points in the production blender; relative standard deviation for active content is commonly required to be ≤ 5.0% for oral premixes, though tighter values may be necessary for low-dose vitamins. Published data for a specific multicomponent veterinary premix at production scale are often limited; the formulation is therefore qualified through blend uniformity and segregation studies on the actual production blend.

Wet granulation reduces segregation but exposes B vitamins to water and heat. Thiamine hydrochloride undergoes hydrolytic degradation in neutral and alkaline media; granulation binder pH should be maintained in the acidic range, preferably pH 3.0–4.5. Drying temperature is normally kept below 55°C for heat-sensitive cyanocobalamin and folic acid unless vacuum drying or low-moisture granulation is validated. Dry granulation or roller compaction may be selected when the API is too water-sensitive for aqueous granulation.

When injectable solutions are the intended dosage form, the selection criteria for the API invert toward endotoxin, particulate, and photoprotection controls

Water solubility is the first discriminator for injectable formulations. Thiamine hydrochloride, pyridoxine hydrochloride, and nicotinamide dissolve readily in water for injection, but riboflavin has aqueous solubility below 0.1 mg/mL at neutral pH; riboflavin 5′-phosphate sodium may be substituted where the monographed form is permitted. Folic acid and biotin are poorly soluble and are usually formulated with pH adjustment, a cosolvent, or as a separately stabilised phase. The API certificate of analysis for injectable grade must include bacterial endotoxins tested according to Ph. Eur. 2.6.14, with the acceptance limit derived from the maximum intended dose; when no product-specific limit is established, injectable-grade APIs are often controlled at ≤ 0.25 EU/mg or tighter.

Terminal sterilisation of B-complex solutions is limited by thermal degradation of thiamine and cyanocobalamin. Aseptic filtration through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane is commonly used; filter compatibility and extractables are assessed with the finished solution. Residual headspace oxygen is controlled by nitrogen sparging because thiamine and cyanocobalamin are sensitive to oxidative degradation. Light exposure contributes to photodegradation of riboflavin and cyanocobalamin; amber borosilicate primary containers or light-protective secondary packaging are specified.

The pH of the finished injection is generally adjusted to 3.0–4.5 because thiamine hydrochloride displays maximum stability in acidic solution and pyridoxine hydrochloride remains stable under acidic conditions. However, riboflavin 5′-phosphate sodium may require a neutral pH to remain soluble, so commercial B-complex injections often contain a solubilised riboflavin derivative or a separate stabilised ampoule. Sulfite antioxidants should be avoided in cyanocobalamin-containing injections because sulfites degrade cyanocobalamin. The final solution must meet particulate matter tests Ph. Eur. 2.9.19 or 2.9.20 and sterility according to Ph. Eur. 2.6.1.

In dry oral solid dosage manufacturing, the flow and compression behaviour of a B-vitamin API blend is evaluated before formulation route selection. Direct compression is often possible when the API is spray-dried, co-processed, or combined with free-flowing directly compressible excipients, but needle-like riboflavin crystals and cohesive calcium D-pantothenate may require wet granulation or roller compaction. Granulation moisture should be controlled because thiamine hydrochloride and cyanocobalamin degrade under elevated heat and humidity. Tablet friability is tested according to Ph. Eur. 2.9.7 and should generally be ≤ 1.0%; disintegration for uncoated tablets is evaluated according to Ph. Eur. 2.9.1 and is commonly ≤ 15 min unless otherwise justified. Dissolution testing uses the test platform described in Ph. Eur. 2.9.3 or USP <711>, but the acceptance criteria are product-specific and established in the veterinary marketing authorisation.

For hard gelatin capsules, the fill moisture content is usually maintained below 10% and storage is controlled at 25°C or lower to avoid shell crosslinking. Riboflavin produces yellow-orange discoloration in tablets and capsule fills; coated tablets or opaque capsules may be specified for visual and photoprotection reasons. The choice of carrier in the API blend, such as lactose, calcium carbonate, or starch, must be declared because lactose-containing APIs may be unsuitable for certain species or feed restrictions.

Veterinary pharmaceutical grade versus feed grade versus human grade: impurity, release testing, and documentation boundaries

The term “veterinary grade” does not by itself define a compendial standard. In pharmaceutical use, each active component must comply with the relevant monograph of the European Pharmacopoeia or United States Pharmacopeia. Feed-grade B-vitamin premixes are often purchased under feed additive regulations, such as Regulation (EC) No 1831/2003 in the European Union, and may tolerate higher levels of residual metals, wider assay ranges, and simpler documentation. Human-grade APIs may differ in residual solvent control, batch changeover procedures, and the format of regulatory documentation; they may be used in veterinary medicinal products only when the specific impurity profile, residual solvents, and physical properties are evaluated for target-species acceptability.

Selection of a veterinary GMP pharmaceutical API rather than a feed-grade blend is required when the finished product will be registered as a veterinary medicinal product. The reverse is not automatically true: feed-grade material should not be introduced into a pharmaceutical manufacturing line without a documented quality upgrade. For injectable products, the API must be low in particulate matter and endotoxin, and the final solution must be filtered through a sterilising-grade membrane. The finished-product manufacturer is responsible for confirming that the selected API grade is compatible with the target species, the specific manufacturing process, and the regulatory file under which the product is authorised.